Andrea Arfe, PhD

Assistant Attending Biostatistician
Andrea Arfe


Bocconi University; Milan, Italy

Current Research Interest

Dr. Arfè’s research interests include statistical decision theory, Bayesian analysis, and reinforcement learning. Dr. Arfè collaborates with investigators in the Genito-Urinary Oncology Service and with members of the MSK Biomarker Development Program to study new blood-based biomarkers in metastatic Castrate-Resistant Prostate Cancer (mCRPC) based on circulating tumor cells. He is also collaborating with investigators in the MSK Department of Radiation Oncology to design a clinical trial of post-operative brachytherapy for early-stage endometrial cancer patients. In his current methodological research, Dr. Arfè aims to develop new adaptive group-sequential clinical trial designs that leverage data from completed studies by means of machine learning methods. In support to his research program, he has been selected to receive Developmental Funds from the Cancer Center Support Grant.


Selected peer-reviewed publications:

  1. Arfè A, Silverman LB, Bourgeois F. Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children: Essential Tools in the Era of the Research to Accelerate Cures and Equity Act. JAMA Oncol. 2021 Sep 1;7(9):1281-1282. doi: 10.1001/jamaoncol.2021.1508. PMID: 34110376.
  2. Arfè A, Alexander B, Trippa L. Optimality of testing procedures for survival data in the nonproportional hazards setting. Biometrics. 2021 Jun;77(2):587-598. doi: 10.1111/biom.13315. Epub 2020 Jun 24. PMID: 32535892.
  3. Arfè A, Fell G, Alexander B, Awad M, Rodig S, Trippa L, Schoenfeld J. Meta-analysis of Programmed Death Factor Ligand 1 expression as a predictive biomarker using individual data on 7,918 randomized study patients. JCO Precision Oncology 2020; 4:1196-1206.
  4. Spring LM*, Fell G*, Arfè A* (*co-primary authors), Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B,  Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clinical Cancer Research 2020; doi: 10.1158/1078-0432.CCR-19-3492.
  5. Arfè A, Ventz S, Trippa L. Shared and usable data from phase I oncology trials: an unmet need. JAMA Oncology 2020; 6:980-981.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Andrea Arfe discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures